Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$9.80 USD
+0.02 (0.16%)
Updated May 31, 2024 10:14 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 81 - 91 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Pieris Pharmaceuticals with a Buy rating and 12- month target price of $7/share
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J